Clinical and Humanistic Outcomes of Community Pharmacy-Based Healthcare Interventions Regarding Medication Use in Older Adults: A Systematic Review and Meta-Analysis

Christina Malini Christopher 1, Bhuvan KC 1,*, Ali Blebil 1, Deepa Alex 2, Mohamed Izham Mohamed Ibrahim 3, Norhasimah Ismail 4 and Alian A. Alrasheedy 5,*

Citation: Christopher, C.M.; KC, B.; Blebil, A.; Alex, D.; Ibrahim, M.I.M.; Ismail, N.; Alrasheedy, A.A. Clinical and Humanistic Outcomes of Community Pharmacy-Based Healthcare Interventions Regarding Medication Use in Older Adults: A Systematic Review and Meta-Analysis. Healthcare 2021, 9, 1577. https://doi.org/10.3390/healthcare9111577

Abstract: This review and meta-analysis aimed to determine the clinical and humanistic outcomes of community pharmacy-based interventions on medication-related problems of older adults at the primary care level. We identified randomized controlled trials (RCTs) examining the impact of various community pharmacy-based interventions from five electronic databases (namely, MEDLINE (Ovid), EMBASE (Ovid), CINAHL, APA PSYInfo, and Scopus) from January 2010 to December 2020. Consequently, we assessed these interventions’ clinical and humanistic outcomes on older adults and compared them with non-intervention. We included 13 RCTs in the current review and completed a meta-analysis with six of them. The included studies had a total of 6173 older adults. Quantitative analysis showed that patient education was significantly associated with an increase in the discontinuation of sedative–hypnotics use (risk ratio 1.28; 95% CI (1.20, 1.36) I² = 0%, p < 0.00001). Moreover, the qualitative analysis showed that medication reviews and education with follow-ups could improve various clinical outcomes, including reducing adverse drug events, reducing uncontrolled health outcomes, and improving appropriate medication use among the elderly population. However, medication review could not significantly reduce the number of older adults who fall (risk ratio 1.25; 95% CI (0.78, 1.99) I² = 0%, p = 0.36) and require hospitalization (risk ratio 0.72; 95% CI (0.47, 1.12) I² = 45%, p = 0.15). This study showed that community pharmacy-based interventions could help discontinue inappropriate prescription medications among older adults and could improve several clinical and humanistic outcomes. However, more effective community pharmacy-based interventions should be implemented, and more research is needed to provide further evidence for clinical and humanistic outcomes of such interventions on older adults.

Keywords: community pharmacy; intervention; older adults; outcomes; systematic review

1. Introduction

There is an ever-increasing need for healthcare services for older adults because of the increase in the aging population. The population of older adults (65 and above) was estimated to be 8.5% of the total population (i.e., 617.1 million) in 2015 and is expected to reach 12% in 2050 (i.e., 1 billion) [1]. The prevalence of multiple chronic illnesses that require comprehensive and complex care is higher in this population. Accordingly, older adults consume a high proportion of prescription medicines and over-the-counter (OTC)
medicines and take multiple medicines to manage their chronic illnesses [2–4]. Health-related problems arise when older adults do not take medicines as prescribed, self-consume medicines, or consume the wrong medicines for various reasons [5].

Medication-use problems of older adults are complex and multifaceted and cause an enormous public health, social, and financial burden to the economy [6,7]. Medication usage problems of older adults can affect the optimal therapeutic outcomes and cause adverse drug events and serious harm. The problems related to medication usage in older adults happen at both secondary/tertiary and primary care levels. In the hospital setting, the involvement of multiple healthcare professionals, via a collaborative care model, and the focus on medication safety can help identify and minimize medication-related problems of older adults. In contrast, in primary care settings, the approach of healthcare delivery mostly focuses on preventing illness and promoting health [8]. In general, the primary care level lacks a geriatric-focused care delivery that can identify complex healthcare and medication usage need of older adults and support them adequately.

Medication usage for the older adults at the primary care level is coordinated via general practitioners (both private and government primary health clinics), community nurses, and community pharmacists. Furthermore, the transition of care for older adults happens from secondary and tertiary healthcare to primary healthcare facilities [9]. Consequently, community pharmacies are a pivotal junction in this entire paradigm, responsible for delivering medications and ensuring appropriate use of medications among older adults.

Several studies have examined the problems of medication use of older adults and the potential for community pharmacists to contribute to appropriate medication use at the primary care level. Studies have reported a post-discharge medication review by community pharmacists and its impact on the aging population [10–12]. A study by Kayyali et al. [13] in the UK has reported problems among older adults such as difficulty in medication administration (40%), lack of monitoring of patients with diabetes, and risk of falling (14.3%). Another study by Foubert et al. [14] conducted among community-dwelling older adults (patients) with polypharmacy and those receiving home health care with medication schemes’ alteration (review) by community pharmacists showed that pharmacists’ interventions enabled more complete and accurate medication schemes. Several reviews have highlighted the improvement in medication adherence among older adults following an intervention by community pharmacists [15–17]. Apart from medication adherence, there was improved quality of life and reduced drug-related problems from these reviews.

Overall, several studies have reported improved health outcomes from various pharmacists’ interventions on older adults’ medication use [18,19]. Some of these interventions were delivered by pharmacists during the transition of care as a collaborative care model with community pharmacists, while some are delivered solely via community pharmacy-based interventions. A systematic review by Cooper et al. [20] regarding pharmacists’ interventions to improve appropriate use of polypharmacy among older adults did not find significant clinical improvements. However, the systematic review evaluated pharmacists’ interventions from both primary and secondary care settings. Likewise, another systematic review by Clyne et al. [21] on pharmacists’ interventions to address potentially inappropriate prescribing in community-dwelling older adults reported that such interventions were beneficial in reducing potentially inappropriate prescribing but with modest effect size. This systematic review included pharmacist’s intervention from different settings, not just the community pharmacy [21]. Thus, from a health system perspective, there is still a need for studies that thoroughly evaluate community pharmacy-based services’ impact with an exclusive focus on older adults’ medication usage problems and relevant clinical and humanistic outcomes. Therefore, this systematic review and meta-analysis aimed to determine the clinical and humanistic outcomes of community pharmacy-based interventions for older adults to solve their medication usage problems. We believe this review will provide evidence for creating and funding a community pharmacy-based appropriate medicine usage support program for older adults.
2. Materials and Methods

The study protocol has been registered at PROSPERO 2021 CRD42021229948 and was developed based on the Cochrane Handbook for Systematic Reviews of Interventions and the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines [22].

2.1. Eligibility Criteria

Studies which specifically included population of older adults aged 65 years and above were eligible for the review. Moreover, community pharmacy-based interventions were the main inclusion criteria. Comparator or control was based on non-intervention or not receiving community pharmacy-based services. The outcome was based on interventions regarding medication use among older adults. Study designs of included studies were randomized controlled studies. The exclusion criteria were studies published in a language other than in English and before the year 2010, studies that are not randomized controlled studies, and studies that are not community pharmacy-based interventions.

2.2. Search Strategy

The electronic search was performed in MEDLINE (Ovid), Ovid EMBASE, CINAHL, APA PSY Info, and Scopus. The search was for original articles describing community pharmacy-based interventions for older adults regarding medication use from January 2010 to December 2020. (Refer supplementary material, Table S1). The search process was taken in three steps. The initial search was completed using Scopus and Medline to explore the literature and become more familiar with the terms and current studies—including analyzing each word/term in the titles and abstracts and identifying index terms in each article. After that, in the second step, a comprehensive search was completed by using all index terms and identifying key terms by using the selected databases. In the third step, references of key articles were searched for additional studies. Studies were restricted to the English language. In addition, grey literature was explored to find any potential studies relevant to the study objectives and eligibility criteria. The entire actual search is available in Table S1.

2.3. Study Selection

Two reviewers (C.M.C. and B.K.C.) screened and reviewed the titles and abstracts of identified studies using the search strategy and those from additional sources (i.e., references of retrieved articles, grey literature, and websites from professional pharmacy societies such as Malaysian Pharmaceutical society) to identify studies that meet the inclusion criteria mentioned earlier. Full-text articles were also screened in the same manner. Any disagreements were resolved by consensus through another reviewer (A.B.). Interventions were included if they were community pharmacy-based, and the study design was a randomized controlled trial. Consequently, other studies not meeting these criteria were excluded, including review articles and conference abstracts.

2.4. Data Extraction

The first author (C.M.C.) extracted data using a standardized form and was checked by the second author (B.K.C.). Data extracted included publication details (author, year of publication, and journal name); study design characteristics (study design, sample size, objectives, country); study characteristics (type of intervention, method of intervention, and outcome of intervention); and the main results of the study.

2.5. Risk of Bias (Quality Assessment)

Two authors (C.M.C and B.K.C.) independently assessed the risk of bias using Cochrane Risk of Bias (ROB 2.0) for randomized controlled trials, which is a revised Cochrane tool [23]. The main domains where bias could arise and judgment of risk of bias needed to be completed include randomization process, deviation from intended interventions, missing
outcome data, measurement of outcome, and the selection of reported results. Consequently, based on the risk-of-bias judgment of each domain in the clinical trial, the overall risk of bias can be judged as low risk of bias, some concerns, or high risk of bias. During the judgment of risk of bias, if there were any discrepancies, both reviewers discussed and resolved them. Moreover, we used the GRADE criteria to assess the quality of evidence for each outcome reported [24].

2.6. Data Analysis

Studies were eligible for the meta-analysis if at least two outcomes were comparable. Cochrane handbook was used as a guide to analyzing our data [25]. Statistical heterogeneity was assessed using the $I^2$ statistic, one of the statistical tools to be present in the meta-analysis study [26]. Heterogeneity was defined as high if $I^2 > 75\%$ and low if $I^2 < 25\%$ [27]. We used a random-effect model in our meta-analysis, assuming that heterogeneity exists within the samples. Results were presented with a risk ratio for the dichotomous variable with a confidence interval of 95%. As a priori, we performed subgroup analyses by the duration of follow-up to review the number of older adults hospitalized. All analyses were performed using Cochrane Review Manager version 5.4. (The Nordic Cochrane Centre, Copenhagen, Denmark).

3. Results

A total of 6917 articles were identified through the selected databases. Another nine articles were retrieved from other sources such as Google Scholar for grey literature, manual search in the key references retrieved, and other websites particularly the Ministry of Health Malaysia and the Malaysian Pharmaceutical Society website. After removing duplications ($n = 1337$), a total of 5589 articles were identified for the title and abstract screening, and 108 articles were included for further review by accessing the full texts and assessing them against the inclusion criteria. Most full texts were excluded because of a non-randomized controlled study design ($n = 49$) and non-community pharmacy-based intervention ($n = 17$). Consequently, 13 randomized controlled trials (RCT) were included in this systematic review. Reasons for the exclusion of full texts and the flow of studies are described in Figure 1. In this review, the inter-rater reliability for the final extraction between two reviewers was 0.918.

3.1. Characteristics of Included Studies

Among the 13 randomized controlled trials, 7 were cluster randomized control trials, 1 was a double-blind RCT, 1 was a single-blind RCT, 3 were RCTs, and 1 was a pilot RCT, as summarized in Table 1. Trials were carried out in Croatia (two studies), the Netherlands (two studies), the USA (two studies), Canada (two studies), Spain (two studies), New Zealand (one study), Denmark (one study), and Finland (one study) The interventions were conducted by community pharmacists either in a community pharmacy or at patient’s home or medical center clinics or home care unit. The included studies had a total of 6173 older adults with a sample size ranging from 39 to 715 participants. In terms of the type of interventions provided, most of the community pharmacy-based interventions were medication review ($n = 7$), education ($n = 4$), pharmaceutical care ($n = 1$), and electronic device reminder ($n = 1$). In terms of the type of measured outcomes, there were various outcomes reported by studies. Some studies reported the impact on hospitalization ($n = 4$), number of potentially inappropriate medicines (PIM) ($n = 3$), rate of sedative–hypnotics use ($n = 2$), time in warfarin therapeutic range ($n = 1$), quality of life ($n = 1$), medication appropriateness ($n = 1$), drug burden ($n = 1$), rate of discontinuing fall-risk inducing drug ($n = 1$), number of adverse drug events ($n = 2$), mortality ($n = 1$), medication adherence ($n = 2$), and uncontrolled health problems ($n = 1$). The details are presented in Table 1.
Figure 1. PRISMA flowchart of the selection process.
Table 1. Characteristics of included studies.

| Author, Year, Country | Study Design, Settings | Interventions                                                                 | Control Sample Size | Intervention Sample Size | Follow-Up Period | Outcomes                                                                 | Conclusion                                                                 |
|-----------------------|------------------------|-------------------------------------------------------------------------------|---------------------|--------------------------|------------------|--------------------------------------------------------------------------|---------------------------------------------------------------------------|
| Bryant et al. [28]    | (2010) New Zealand     | Randomized, controlled trial, Community pharmacy                             | 143                 | 207                      | 6 months and 12 months | Quality of Life (SF-36) and Medication Inappropriateness Index (MAI), number of inappropriate medications | Medication review improved MAI and reduced the number of potentially inappropriate medicines at 6 months follow-up. However, this intervention did not produce a significant improvement in quality of life. |
| Falamic et al. [29]   | (2019) Croatia         | Randomized, controlled trial, Community pharmacy                             | 66                  | 65                       | 6 months          | The incidence and type of adverse drug reactions caused by warfarin      | The cumulative incidence of adverse drug reactions was significantly lower in the intervention group. |
| Mott et al. [30]      | (2016) United States   | Cluster-randomized, controlled trial, Community pharmacy                    | 41                  | 39                       | 6 months          | Rate of discontinuing the fall-risk inducing drug                        | Medication review significantly improved the rate of discontinuation of fall-risk-inducing drugs among older adults and reduced the number of falls. |
| Touchette et al. [31] | (2012) United States   | Randomized, controlled trial, Academic medical center, community pharmacies, and family medicine clinics | 208                 | Basic MTM = 211 Enhanced MTM = 218 | 6 months          | Frequency of adverse drug events and hospitalization                    | Medication review did not have a beneficial impact on adverse drug events and hospitalization. |
| Author, Year, Country | Study Design, Settings | Interventions | Control Sample Size | Intervention Sample Size | Follow-Up Period | Outcomes | Conclusion |
|-----------------------|------------------------|---------------|---------------------|-------------------------|----------------|---------|------------|
| Varas–Doval et al. [32] (2020) Spain | Open-label, multi-center, cluster-randomized, controlled trial, Community pharmacy | IG: Medication review with follow-up CG: Usual care | 715 | 688 | 6 months | Uncontrolled health problems | Medication review benefited, with a significant reduction in the number of uncontrolled health problems. |
| Olesen et al. [33] (2014) Denmark | Cluster-randomized, controlled trial, Patient’s home | IG: Pharmaceutical care (examining medication list of older adults, answering any questions on their medications, providing leaflets and motivational adherence support) CG: Usual care | 264 | 253 | 3, 6, 9, and 24 months | Medication adherence, hospitalization, and mortality | Pharmaceutical care did not bring a beneficial impact on medication adherence, hospitalization, and mortality among older adults. |
| Toivo et al. [34] (2019) Finland | Cluster-randomized, controlled trial, Community pharmacy, homecare units, public health care center | IG: Collaborative coordination of care (medication review and triage meeting) CG: Standard home care | 87 | 104 | 12 months | Potentially inappropriate medication | No significant findings were found on the impact of coordination of care on outcomes of older adults’ health. |
| Malet-Larrea et al. [35] (2016) Spain | Cluster-randomized, controlled trial, Community pharmacy | IG: Medication review with follow-up CG: Usual care | 715 | 688 | 6 months | Hospitalization | The probability of being hospitalized was 3.7 times higher in the non-intervention group. Thus, medication review had reduced the number of older adults hospitalized. |
| Author, Year, Country | Study Design, Settings | Interventions | Control Sample Size | Intervention Sample Size | Follow-Up Period | Outcomes | Conclusion |
|-----------------------|-----------------------|---------------|---------------------|-------------------------|-----------------|----------|------------|
| Tannenbaum et al. [36] (2014) Canada | Cluster-randomized, controlled trial, Community pharmacy | IG: Patient education (materials which also contained benzodiazepine safety and tapering dose) CG: Usual care | 155 | 148 | 6 months | Benzodiazepine therapy discontinuation | Patient education improved the benzodiazepine discontinuation rate among older adults. |
| Van Der Meer et al. [37] (2018) Netherlands | Single-blind, randomized, controlled trial, Community pharmacy | IG: Medication review with follow-up CG: Usual care | 82 | 75 | 3 months | Drug burden index, hospitalization | Medication review did not have significant effects on the number of falls and hospitalization. Moreover, it did not produce an impact on the difference in drug burden index between groups. |
| Martin et al. [38] (2018) Canada | Cluster-randomized, controlled trial, Community pharmacy | IG: Patient education (education materials were distributed), and education materials were given to prescribers CG: Usual care | 241 | 248 | 6 months | Sedative-hypnotics (benzodiazepine therapy discontinuation) and potentially inappropriate medication | Patient education reduced the number of benzodiazepine users and reduced the number of inappropriate medications among older adults. |
| Falamic et al. [39] (2018) Croatia | Prospective, double-blind, randomized, controlled trial, Community pharmacy | IG: Education and follow-up plan with medication review (given a form containing lab values, INR, and pillbox. CG: Usual GP care | 66 | 65 | 6 months | Time in therapeutic range of warfarin | Patient education improved time in the therapeutic range of warfarin. |
3.2. Risk of Bias Assessment

Figure 2 shows the risk of bias of all the included studies in each domain. Overall, four studies were judged to have a low risk of bias, seven studies were judged to have some concerns regarding the level of risk, and two studies had a high risk of bias. Five studies raise some concerns regarding potential biases in the randomization process [28–32]. All studies did not deviate from intended interventions. Only one study reported some concerns regarding biases on missing outcome data [33]. Two studies did not report a measurement of outcome [32,34]. Some studies were judged to have a selection of reporting biases but were judged to have “some concerns” [28–33,35,36].

| Study ID          | D1 | D2 | D3 | D4 | D5 | Overall |
|-------------------|----|----|----|----|----|---------|
| Bryant et al. [28] |    |    |    |    |    | Low risk |
| Falamic et al. [39]|    |    |    |    |    | Some concerns |
| Falamic et al. [29]|    |    |    |    |    | High risk |
| Kooy et al. [40]   |    |    |    |    |    |          |
| Malet-Larrea et al. [35]|    |    |    |    |    |          |
| Martin et al. [38] |    |    |    |    |    |          |
| Mott et al. [30]   |    |    |    |    |    |          |
| Olesen et al. [33] |    |    |    |    |    |          |
| Tannenbaum et al. [36]|    |    |    |    |    |          |
| Toivo et al. [34]  |    |    |    |    |    |          |
| Touchette et al. [31]|    |    |    |    |    |          |
| Van Der Meer et al. [37]|    |    |    |    |    |          |
| Varas-Doval et al. [32]|    |    |    |    |    |          |

D1 Randomisation process
D2 Deviations from the intended interventions
D3 Missing outcome data
D4 Measurement of the outcome
D5 Selection of the reported result

Figure 2. Risk of bias assessment of included studies.

3.3. Types of Community Pharmacists’ Interventions
3.3.1. Medication Review

Most of the studies (n = 7) performed medication reviews as their main intervention. Comprehensive medication reviews were initiated by interviewing older adults; screening their medication list, lab values, and complementary medicines; and a pharmacotherapeutic plan was decided [28,30–32,34,35,37]. Then, the plan was discussed with prescribers and patients. Finally, the plan was executed with follow-up monitoring by the community pharmacist [28,30–32,34,35,37]. One study had implemented medication review as their main intervention under the coordination of care with other primary health care providers [34].
The study by Touchette et al. [31] included two groups as interventions: basic medication review care and medication review enhanced care. The difference between both is that the latter group had access to clinical information regarding laboratory values of patients, and the former did not have access to the information. In this review, we included the medication review enhanced care as the intervention since it included a comprehensive review with patient lab findings and usual care as a control group.

3.3.2. Educational Intervention

Four RCTs examined the impact of educational intervention [29,36,38,39]. Under this intervention, two studies included a follow-up plan. Participants were provided with a form containing lab values, INR, and important education points and were given a pillbox [29,39]. Tannenbaum et al. [36] provided patient education materials that also contained a tapering benzodiazepine dose in a separate study. Martin et al. [38] mentioned that their study included education materials, including on tapering benzodiazepine dose, distributed to patients and prescribers provided with basic educational materials.

3.3.3. Pharmaceutical Care

This intervention was undertaken by a community pharmacist initially examining the medication list of older adults, answering any questions on their medications, and providing leaflets and motivational adherence support [33]. Older adults would then be followed up after 3, 6, and 9 months, and any drug-related problems involved consultation with prescribers. This intervention differs from a comprehensive medication review because it includes no pharmacotherapeutic plan to be discussed with the prescribers before dispensing the medications to older adults.

3.3.4. Electronic Reminder Device

Only one study implemented this intervention with brief counseling to assess whether it improved refill adherence and persistence for statin treatment in non-adherent older adults [40].

3.4. The Outcomes of the Interventions

3.4.1. Hospitalization

Three studies specifically examined the impact of medication review on the hospitalization of older adults [31,35,37]. In one of the studies, Touchette et al. [31] reported outcomes based on a shorter follow-up duration of three months and a longer duration of six months. The quantitative analysis showed that these three pooled studies did not show a statistically significant impact of medication review on the probability of hospitalization (risk ratio 0.72; 95% confidence interval (0.47, 1.12)) (Figure 3).

![Figure 3](https://www.mdpi.com/journal/... study was part of co-
ordinated care involving other healthcare professionals. The results are summarized in 
Table 1.

| Study or Subgroup | Medication review | Usual Care | Weight | M.H. Risk Ratio | Random, 95% CI |
|-------------------|-------------------|------------|--------|----------------|---------------|
| Medic 2018        | 31                | 60         | 62     | 7.5            | 43.5%         |
| Touchette 2012    | 20                | 75         | 20     | 0.75           | 18.4%         |
| Van Der Meer 2018 | 2                 | 20         | 9      | 0.99           | 3.4%          |
| Total             | 591               | 1054       | 100.0% | 0.72 (0.47, 1.12) |

3.4.2. Sedative–Hypnotics Users

Two studies were using sedative–hypnotics (benzodiazepine) as their outcome assessment drug [36,38]. Both studies were pooled, and patient education was statistically significant for reducing the number of sedative–hypnotics users (risk ratio 1.28; 95% confidence interval (1.20, 1.36)) (Figure 4).
3.4.3. Number of Older Adults Who Fall

Two studies were pooled to assess the medication review intervention on the number of older adults’ falls [30,37]. Both studies were not statistically significant for reducing the number of older adults who fall (risk ratio 1.25; 95% confidence interval (0.78, 1.99) I² = 0%, p = 0.36) (Figure 5).

3.4.4. Potentially Inappropriate Medications

Three studies reported the number of potentially inappropriate medicines as the outcome of the intervention. Martin et al. [38] reported that at 6 months, 43% in the intervention group did not have prescriptions for inappropriate medicines compared with only 12% in the control group. Moreover, Bryant et al. [28] reported that the mean number of inappropriate medicines per patient was higher for the intervention group at baseline (2.5) and reduced after 6 months of intervention (2.5 versus 1.6, respectively, p < 0.001) compared to the control group (2.1 versus 2.1, respectively, p = 0.991). Another study by Toivo et al. [34] did not have significant findings based on their intervention on the potentially inappropriate medication. However, the role of pharmacists in this study was part of coordinated care involving other healthcare professionals. The results are summarized in Table 1.

3.4.5. Medication Adherence

One RCT that examined the impact of one type of pharmaceutical care did not report a significant impact on medication adherence as per the study by Olesen et al. [33]. Similarly, with the electronic reminder device intervention, no improvement of refill adherence was found in the older adults’ population [40].

3.4.6. Adverse Drug Events

Two studies measured the impact of the interventions in terms of adverse drug events. One study by Falamic et al. [29] highlighted that adverse drug reactions were significantly lower in the group of older adults who were prescribed warfarin and were receiving an educational intervention. The author described that providing patient education on warfarin, pillbox, and a follow-up plan reduced the risk of bleeding as an adverse drug event. Meanwhile, Touchette et al. [31] mentioned no significant impact on adverse drug events after providing medication reviews. However, overall, community-pharmacy-based interventions managed to reduce the number of adverse drug events through patient education.
3.4.7. Other Outcomes

A study by Bryant et al. [28] stated that through medication review, the medication appropriateness index improved, but it did not improve the quality of life in the intervention group. Meanwhile, Mott, Martin [30] described that the intervention group had a significant impact by leading to a higher rate of discontinuing fall-risk-inducing drugs among older adults after medication review completed by the community pharmacist. Another study by Varas–Doval et al. [32] had a significant reduction in the number of uncontrolled health problems after the same intervention. Despite that, Olesen et al. [33] reported no significant improvement in mortality rate after medication adherence was completed. As for educational interventions, Falamic et al. [39] pointed out that it improved warfarin’s therapeutic time range in older adults. As a whole, various community pharmacy-based interventions show improvement in clinical outcomes among older adults. However, evidence is lacking regarding patient satisfaction and quality of life in these studies.

3.5. Sensitivity Analysis

Moderate heterogeneity, $I^2 = 45\%$, was found in the outcome of hospitalization. Thus, a one-on-one removal of studies in the meta-analysis was completed by removing a study by Touchette et al. [31] in the hospitalization outcome, and subsequently, no heterogeneity was found. This analysis reported that medication review was significant for reducing hospitalization of older adults (risk ratio 0.59; 95% confidence interval (0.39, 0.88)) $I^2 = 0\%$, $p = 0.01$. (Figure 6)

![Forest plot of sensitivity analysis showing risk ratio of older adults hospitalized after medication review intervention.](image)

3.6. Subgroup Analysis

Subgroup analysis comparing studies that reported hospitalization after three months and six months medication reviews were completed (Table 2). The effect of the intervention was not statistically significant between the duration of follow-up of subgroups (risk ratio 0.74; 95% confidence interval (0.54, 1.00)) $I^2 = 18\%$, $p = 0.05$ (Figure 7).

| Outcome        | Number of Studies | Number of Participants | Statistical Method                  | Effect Size 95% (CI) |
|----------------|-------------------|------------------------|------------------------------------|----------------------|
| Hospitalization| 3 [31,35,37]      | 1986                   | Risk ratio (M–H, random, 95% CI)   | 0.74 (0.54,1.00)     |
| 3 months       | 2 [31,35]         | 583                    | Risk ratio (M–H, random, 95% CI)   | 0.62 (0.35,1.11)     |
| 6 months       | 2 [31,37]         | 190                    | Risk ratio (M–H, random, 95% CI)   | 0.78 (0.50,1.23)     |
Figure 7. Forest plot showing subgroup analysis of the risk ratio in older adults’ hospitalization according to the duration of follow-up after medication review intervention.

### 3.7. Certainty of Evidence

Based on GRADE criteria, the certainty of the evidence was rated as moderate for the outcome of hospitalization. Outcomes of the number of older adults who fell and ceased benzodiazepine were rated as high-quality based on GRADE criteria.

### 4. Discussion

To the best of our knowledge, this meta-analysis is probably the first study that focused exclusively on the impact of community pharmacy-based interventions on medication use and related clinical and humanistic outcomes among the older population (i.e., 65 years and over). Previous studies have focused on a particular intervention that was carried out within and outside community pharmacy settings and focused on medications usage problems of both the general population and older adults [41–44]. This review focused on various community pharmacy-based services/interventions for medications usage problems of older adults and its impact based on the best available evidence (i.e., RCTs).

Previous reviews (systematic review and meta-analysis) have focused on various interventions by pharmacists regarding medication usage problems. However, they looked at the outcomes of pharmacists’ interventions regarding medication usage problems of both the general population and older adults (i.e., mixed populations) and reviewed interventions that were carried out by pharmacists working in both primary and secondary care settings (i.e., different settings) [45–48]. These reviews focused on all types of community pharmacy-based services, and these were not exclusively focused on any specific sub-group of the population. Thus, so far, only one systematic review by Tasai et al. [16] focused on the medication usage problems of the elderly population; however, it also only looked at the impact of medication review on one service (i.e., polypharmacy) in the elderly population. The current systematic review and meta-analysis are different from other studies and reviews as they critically review all the eligible community pharmacy-based services, focusing on medication usage problems of older adults in particular.

Community pharmacy-based interventions were regarded as one of the most accessible primary services by the older population. Most of the interventions were provided by community pharmacies in collaboration with other healthcare professionals, including physicians, general practitioners, and nurses. As a whole, there is evidence in the literature that community pharmacy-based interventions impacted several clinical outcomes among older adults, including reducing inappropriate medicine use (including that of sedative–hypnotics); reducing uncontrolled health problems; and potentially reducing ADRs. However, evidence was lacking in terms of the impact on patient satisfaction and...
quality of life. Consequently, given the limited literature for studies focused on the elderly population in the community pharmacy setting (i.e., RCTs), more research is needed in this area.

The current review showed that patient education delivered by community pharmacists increased the number of older adults who benefited from the pharmacists’ interventions and discontinued their sedative–hypnotic drugs. For example, we found that patient education improved the cessation of benzodiazepine among older adults. This is in line with a previous review in which education improved the number of older adults who ceased benzodiazepine [49]. However, Reeve, Ong [50], in their review, reported that the rate of benzodiazepine discontinuation was lower with patient education compared with other interventions. However, the differences could be explained by the fact that patient education could be provided in different ways, and hence its impact could be different depending on the type, structure, and nature of the educational intervention. We have noted that the patient education included in our review was thorough and innovative. For example, it was provided together with the visual tapering dose, which is a method of effective intervention leading to the reduced use of benzodiazepine. Brochures on educational materials have also influenced the choices of hypnotic–sedative users. In addition, patient education helps provide knowledge on sedative–hypnotic medication, including its risks and side effects for patients. Consequently, this information provides evidence for supporting this professional service and could be further expanded as part of a collaborative health care model in the primary care setting.

Various community pharmacy-based interventions were identified in this systematic review and meta-analysis. Among various interventions, medication review was the most common intervention carried out by the community pharmacists and was evaluated in RCTs. Varas–Doval et al. [32] reported that medication review with follow-up resulted in a significant reduction in the number of uncontrolled health problems over 6 months in the intervention group compared to no change in the control group. Moreover, it was shown that medication reviews and education by community pharmacists targeting elderly patients resulted in better outcomes in terms of appropriate medication use [28,38]. However, medication reviews by community pharmacists did not reduce the probability of hospitalization among older adults, in contrast with the previous findings of Tasai, Kumpat et al. [16] and Jokanovic et al. [17] on this outcome. However, our findings were on par with several other reviews [51–53]. This is possibly because there are only limited studies with moderate heterogeneity in the literature, which cause a non-significance impact; however, significant findings were noted when sensitivity analysis was completed in our review. In the literature, similar to the hospitalization outcomes, mixed results were reported regarding the impact of medication reviews on the risk of falls. Our current study showed that medication reviews did not reduce the number of older adults falling. Similar to our findings, Hart, Phelan [54], and colleagues pointed out that medication review did not reduce the number of older adults who fall in their review. However, another study by Huiskes et al. [51] indicated that medication review decreased the number of older adults falling. Several factors could explain the differences among the results, including self-reporting. The two studies included in our meta-analysis were based on patient self-reporting findings [30,37]. Thus, the possibility of not accurately revealing the number of older adults who fall is high due to old-aged patients’ frail conditions. Moreover, the study by Mott et al. [30] was a pilot study, and the sample size was limited. Thus, this might explain the non-significance results. Consequently, we believe more research is needed to further investigate the impact of community pharmacists’ intervention on these outcomes. In addition, more structured and tailored interventions are needed to be established at the community pharmacies to provide quality services to the elderly population.

There was evidence of a reduction in the inappropriate medications in one of the included studies through patient education on other outcomes [38]. Moreover, Falamic et al. [29] provided education with a pillbox, and adverse drug events were significantly reduced among older adults prescribed warfarin. Kallio et al. [15] justified that most studies showed
improvement in medication adherence and reduced drug-related problems among older patients after medication review intervention is completed by community pharmacists. Our systematic review shows some evidence of improvement in medication adherence because of community pharmacy-based interventions. However, when it comes to long term impact, such as the effect of community-pharmacy-based interventions on quality of life, we found limited evidence, with one study by Bryant et al. [28] not showing an impact, which is similar to the results from Huiskes et al. [51]. Several recent studies have investigated telephone calls and automated telephonic prompts as a digital tool, and medication adherence was the most included topic in the digital conversation between community pharmacists and patients [55]. However, these studies did not include any specific population, and there were no studies found on social media platforms as a digital tool, especially involving the older adult population.

Overall, our findings revealed that community pharmacy services are beneficial to older adults to optimize proper medication use, reduce unnecessary benzodiazepine use, reduce uncontrolled health problems, and ADRs among older adults. Therefore, evidence-based educational interventions should be encouraged in community pharmacies to achieve rational medication use among older adults visiting community pharmacies and to provide further improvements in their health.

4.1. Strengths and Limitation

The current review has some points of strength. First, we have only considered randomized, controlled trials in our review, and this increased the robustness of the study [56]. Furthermore, we have assessed the outcomes of quantitative analysis through GRADE criteria and only included moderate- and high-quality studies. Heterogeneity across studies was also assessed with sensitivity analysis, and we have reported the homogeneity of studies after removing one study. Our search narrowed to community pharmacy-based interventions, focusing on the older population, which was an added advantage to review older adults’ health care outcomes. However, there are several limitations to this review. Firstly, the search articles for this review were restricted to the English language. Thus, we acknowledge that there might be a limitation to the search in non-English native regions. Secondly, the age limit for older adults in this review was 65 years and above. Therefore, we could not have captured studies that included older adults in the range of 60 years and above. Thirdly, our review resulted in various interventions with different features in terms of the duration, nature, and components of the intervention. Lastly, we could not determine the pooled estimates for other outcomes—medication adherence, quality of life, potentially inappropriate medication, and adverse drug events—because of different outcomes with various interventions. In addition, there were limited RCTs on several outcomes of interest such as adherence, quality of life, etc. However, overall, we believe the current review and meta-analysis provided useful data for future guidance to improve the pharmaceutical care services provided to the older population at community pharmacies.

4.2. Implications for Research and Practice

It is well known that community pharmacy is one of the most accessible health care resources and could play a fundamental role in the health care of older adults in a community [16]. However, there are limited RCTs that evaluated the impact of interventions and services in community pharmacies on the health outcomes of populations aged 65 years and over. Consequently, given the rapid surge in the aging population, more future research is needed to implement pharmacists’ interventions and evaluate their clinical, humanistic, and economic outcomes among older adults. In addition, more qualitative exploration focusing on older adults’ mobility, hearing, etc., and other access problems at community pharmacies should be explored. The role of a community pharmacy in certain lower- and middle-income countries (LMICs) still lacks the recognition as primary health care providers. Many older adults in these regions still access tertiary health care as their first
point of care. Therefore, this review will help provide an evidence for the development of community pharmacy-based interventions focused on reducing medication-related problems of older adults in the LMICs. Furthermore, future research should look at the integration of pharmacists in the primary care system so that they can provide long-term support for older adults, focusing on the appropriate use of medicines among older adults. It will ease the rising burden of general practitioners in primary care settings and establish pharmacists’ services as an integral element of geriatric-focused primary care service.

5. Conclusions

The current review showed that there are several healthcare interventions conducted by community pharmacists for the elderly population. The most common interventions evaluated by RCTs included medication reviews and educational interventions. Moreover, there is evidence in the literature that community pharmacy-based interventions have a beneficial impact on clinical outcomes among older adults, including a reduction in inappropriate medicine use (e.g., sedative–hypnotic drugs), reduction in uncontrolled health problems, and reduction of ADRs. There is limited or inconclusive evidence on the impact of community pharmacists’ interventions on hospitalization, quality of life, and other outcomes from RCTs. Consequently, we believe more research is needed to further investigate the impact of community pharmacists’ intervention on these outcomes. In addition, more structured and tailored interventions are needed to be established at community pharmacies to provide quality services to the elderly population in collaboration with other healthcare professionals (i.e., medical practitioners and nurses) and in an integrated manner within the primary care system.

Supplementary Materials: The following are available online at https://www.mdpi.com/article/10.3390/healthcare9111577/s1, Table S1: Search Strategy.

Author Contributions: Conceptualization, C.M.C., B.K. and A.B.; methodology, C.M.C., B.K. and D.A.; validation, A.B. and D.A.; formal analysis, C.M.C. and B.K.; Writing—original draft preparation, C.M.C., B.K., and A.A.A.; writing—review and editing, B.K., A.B., D.A., M.I.M.I., N.I., and A.A.A. supervision, B.K.; project administration, B.K. and A.A.A. All authors have read and agreed to the published version of the manuscript.

Funding: This research received no external funding.

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Data Availability Statement: The authors confirm that data supporting the findings of this study are available within the article and its Supplementary Materials.

Acknowledgments: The authors would like to thank Sunil Shrestha for his invaluable contributions in providing inputs on data extraction and assessing the quality of included studies.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. He, W.; Goodkind, D.; Kowal, P.R. An Aging World, International Population Reports; U.S. Government Printing Office: Washington, DC, USA, 2015.
2. Amoako, E.P.; Richardson-Campbell, L.; Kennedy-Malone, L. Self-Medication with Over-The-Counter Drugs Among Elderly Adults. J. Gerontol. Nurs. 2003, 29, 10–15. [CrossRef] [PubMed]
3. Kim, J.; Parish, A.L. Polypharmacy and Medication Management in Older Adults. Nurs. Clin. N. Am. 2017, 52, 457–468. [CrossRef] [PubMed]
4. Scott, I.A.; Hilmer, S.N.; Reeve, E.; Potter, K.; Le Couteur, D.; Rigby, D.; Gnijdic, D.; Del Mar, C.B.; Roughhead, E.E.; Page, A.; et al. Reducing Inappropriate Polypharmacy. JAMA Intern. Med. 2015, 175, 827–834. [CrossRef]
5. Balbuena, F.R.; Aranda, A.B.; Figueras, A. Self-Medication in Older Urban Mexicans. Drugs Aging 2009, 26, 51–60. [CrossRef]
6. Chiatti, C.; Bustacchini, S.; Furneri, G.; Mantovani, L.G.; Cristiani, M.; Misuraca, C.; Lattanzio, F. The Economic Burden of Inappropriate Drug Prescribing, Lack of Adherence and Compliance, Adverse Drug Events in Older People. Drug Saf. 2012, 35, 73–87. [CrossRef]
7. Aparasu, R.R.; Mort, J.R. Prevalence, correlates, and associated outcomes of potentially inappropriate psychotropic use in the community-dwelling elderly. *Am. J. Geriatr. Pharmacother.* 2004, 2, 102–111. [CrossRef]
8. Bennett, J.A.; Flaherty-Robb, M.K. Issues affecting the health of older citizens: Meeting the challenge. *Online J. Issues Nurs.* 2003, 8, 2.
9. Baillie, L.; Gallini, A.; Corser, R.; Elworthy, G.; Scotch, A.; Barrand, A. Care transitions for frail, older people from acute hospital wards within an integrated healthcare system in England: A qualitative case study. *Int. J. Integr. Care* 2014, 14, e009. [CrossRef]
10. Ramsbottom, H.; Rutter, P.; Fitzpatrick, R. Post discharge medicines use review (dMUR) service for older patients: Cost-savings from community pharmacist interventions. *Res. Soc. Adm. Pharm.* 2018, 14, 203–206. [CrossRef] [PubMed]
11. Ramsbottom, H.F.; Fitzpatrick, R.; Rutter, P. Post discharge medicines use review service for older patients: Recruitment issues in a feasibility study. *Int. J. Clin. Pharm.* 2016, 38, 208–212. [CrossRef] [PubMed]
12. Rutter, P.; Ramsbottom, H.; Fitzpatrick, R. Community pharmacist perceptions of delivering post-hospital discharge Medicines Use Reviews for elderly patients. *Int. J. Clin. Community Pharm.* 2017, 39, 33–36. [CrossRef] [PubMed]
13. Kayyali, R.; Funnell, G.; Harrap, N.; Patel, A. Can community pharmacy successfully bridge the gap in care for housebound patients? *Res. Soc. Adm. Pharm.* 2019, 15, 425–439. [CrossRef]
14. Foubert, K.; Mehuyès, E.; Claes, L.; Abeele, D.V.D.; Haems, M.; Somers, A.; Petrovic, M.; Boussery, K. A shared medication scheme for community dwelling older patients with polypharmacy receiving home health care: Role of the community pharmacist. *Acta Clin. Belg.* 2018, 74, 326–333. [CrossRef]
15. Kallio, S.E.; Kiiski, A.; Airaksinen, M.S.; Mäntylä, A.T.; Kumpusalo-Vauhkonen, A.E.; Järvensivu, T.P.; Pobjanoks-Mäntylä, M.K. Community Pharmacists’ Contribution to Medication Reviews for Older Adults: A Systematic Review. *J. Am. Geriatr. Soc.* 2018, 66, 1613–1620. [CrossRef]
16. Tasai, S.; Kumpat, N.; Dilokthornsakul, P.; Chaiyakunapruk, N.; Saini, B.; Dhippayom, T. Impact of Medication Reviews Delivered by Community Pharmacist to Elderly Patients on Polypharmacy: A Meta-analysis of Randomized Controlled Trials. *J. Patient Saf.* 2021, 17, 290–298. [CrossRef]
17. Jokanovic, N.; Tan, E.; Sudhakaran, S.; Kirkpatrick, C.; Dooley, M.J.; Ryan-Atwood, T.E.; Bell, J.S. Pharmacist-led medication review in community settings: An overview of systematic reviews. *Res. Soc. Adm. Pharm.* 2017, 13, 661–685. [CrossRef] [PubMed]
18. Banning, M. A review of interventions used to improve adherence to medication in older people. *Int. J. Nurs. Stud.* 2009, 46, 1505–1515. [CrossRef]
19. Loganathan, M.; Singh, S.; Franklin, B.D.; Bottle, A.; Majeed, A. Interventions to optimise prescribing in care homes: Systematic review. *Age Ageing* 2011, 40, 150–162. [CrossRef]
20. Cooper, J.A.; Cadogan, C.A.; Patterson, S.M.; Kerse, N.; Bradley, M.C.; Ryan, C.; Hughes, C.M. Interventions to improve the appropriate use of polypharmacy in older people: A Cochrane systematic review. *BMJ Open* 2015, 5, e009235. [CrossRef]
21. Clyne, B.; Fitzgerald, C.; Quinlan, A.; Hardy, C.; Galvin, R.; Fahey, T.; Smith, S. Interventions to Address Potentially Inappropriate Prescribing in Community-Dwelling Older Adults: A Systematic Review of Randomized Controlled Trials. *J. Am. Geriatr. Soc.* 2016, 64, 1210–1222. [CrossRef] [PubMed]
22. Liberati, A.; Altman, D.G.; Tetzlaff, J.; Mulrow, C.; Gotzsche, P.C.; Ioannidis, J.P.; Clarke, M.; Devereaux, P.; Kleijnen, J.; Moher, D. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: Explanation and elaboration. *J. Clin. Epidemiol.* 2009, 62, e1–e34. [CrossRef]
23. Sterne, J.A.C.; Savović, J.; Page, M.J.; Elbers, R.G.; Blencowe, N.S.; Bouter, I.; Cates, C.J.; Cheng, H.-Y.; Corbett, M.S.; Eldridge, S.M.; et al. RoB 2: A revised tool for assessing risk of bias in randomised trials. *BMJ* 2019, 366, l4898. [CrossRef] [PubMed]
24. Guyatt, G.; Oxman, A.D.; Akl, E.A.; Kunz, R.; Vist, G.; Brozek, J.; Norris, S.; Falck-Ytter, Y.; Glasziou, P.; DeBeer, H.; et al. GRADE guidelines: 1. Introduction—GRADE evidence profiles and summary of findings tables. *J. Clin. Epidemiol.* 2011, 64, 383–394. [CrossRef]
25. Higgons, J.P.; Thomas, J.; Chandler, J.; Cumpton, M.; Li, T.; Page, M.J.; Welch, V.A. Cochrane Handbook for Systematic Reviews of Interventions, 2nd ed.; John Wiley & Sons: Hoboken, NJ, USA, 2019.
26. Higgons, J.P.T.; Thompson, S.G. Quantifying heterogeneity in a meta-analysis. *Stat. Med.* 2002, 21, 1539–1558. [CrossRef]
27. Higgons, J.P.T.; Thompson, S.G.; Deeks, J.J.; Altman, D.G. Measuring inconsistency in meta-analyses. *Br. Med. J.* 2003, 327, 557–560. [CrossRef]
28. Bryant, L.J.; Coster, G.; Gamble, G.; McCormick, R.N. The General Practitioner–Pharmacist Collaboration (GPPC) study: A randomised controlled trial of clinical reviews in community pharmacy. *Int. J. Pharm. Pract.* 2011, 19, 94–105. [CrossRef]
29. Falamić, S.; Lucijanic, M.; Ortnner-Hadžiabić, M.; Marušić, S.; Bačić-Vrca, V. Pharmacists’ influence on adverse reactions to warfarin: A randomised controlled trial in elderly rural patients. *Int. J. Clin. Pharm.* 2019, 41, 1166–1173. [CrossRef] [PubMed]
30. Mott, D.A.; Martin, B.; Breslow, R.; Michaels, B.; Kirchner, J.; Mahoney, J.; Margolis, A. Impact of a medication therapy management intervention targeting medications associated with falling: Results of a pilot study. *J. Am. Pharm. Assoc.* 2016, 56, 22–28. [CrossRef] [PubMed]
31. Touchette, D.R.; Masica, A.L.; Dolor, R.; Schumock, G.T.; Choi, Y.K.; Kim, Y.; Smith, S.R. Safety-focused medication therapy management: A randomized controlled trial. *J. Am. Pharm. Assoc.* 2012, 52, 603–612. [CrossRef]
32. Varas-Doval, R.; Gastelurrutia, M.A.; Benrimoj, S.I.; García-Cárdenas, V.; Sáez-Benito, L.; Martínez-Martínez, F. Clinical impact of a pharmacist-led medication review with follow up for aged polypharmacy patients: A cluster randomized controlled trial. Pharm. Pract. 2020, 18, 2133. [CrossRef] [PubMed]

33. Olesen, C.; Harbig, P.; Buus, K.M.; Barat, I.; Damsgaard, E.M. Impact of pharmaceutical care on adherence, hospitalisations and mortality in elderly patients. Int. J. Clin. Pharm. 2013, 36, 163–171. [CrossRef] [PubMed]

34. Toivo, T.; Airaksinen, M.; Dimitrow, M.; Savela, E.; Pelkonen, K.; Kiuru, V.; Suominen, T.; Uunimäki, M.; Kivelä, S.-L.; Leikola, S.; et al. Enhanced coordination of care to reduce medication risks in older home care clients in primary care: A randomized controlled trial. BMC Geriatr. 2019, 19, 332. [CrossRef] [PubMed]

35. Malet-Larrea, A.; Goyenechea, E.; García-Cárdenas, V.; Calvo, B.; Arteche, J.M.; Araneu, P.; Zubeldia, J.J.; Gastelurrutia, M.A.; Martínez-Martínez, F.; Benrimoj, S. The impact of a medication review with follow-up service on hospital admissions in aged polypharmacy patients. Br. J. Clin. Pharmacol. 2016, 82, 831–838. [CrossRef]

36. Tannenbaum, C.; Martin, P.; Tamblyn, R.; Benedetti, A.; Ahmed, S. Reduction of Inappropriate Benzodiazepine Prescriptions Among Older Adults Through Direct Patient Education. JAMA Intern. Med. 2014, 174, 890–898. [CrossRef]

37. Van der Meer, H.; Wouters, H.; Pont, L.G.; Taxis, K. Reducing the anticholinergic and sedative load in older patients on polypharmacy by pharmacist-led medication review: A randomised controlled trial. BMJ Open 2018, 8, e019042. [CrossRef]

38. Martin, P.; Tamblyn, R.; Benedetti, A.; Ahmed, S.; Tannenbaum, C. Effect of a pharmacist-led educational intervention on inap propriate medication prescriptions in older adults: The D-PRESCRIBE randomized clinical trial. JAMA 2018, 320, 1889–1898. [CrossRef]

39. Falamić, S.; Lucijanic, M.; Hadžiabdić, M.O.; Marušić, S.; Vrca, V.B. Pharmacist’s interventions improve time in therapeutic range for warfarin patients: A randomized trial. Int. J. Clin. Pharm. 2019, 1078–1085. [CrossRef]

40. Kooy, M.; Van Wijk, B.L.; Heerdink, E.R.; De Boer, A.; Bouvy, M.L. Does the use of an electronic reminder device with or without counseling improve adherence to lipid-lowering treatment? The results of a randomized controlled trial. Front. Pharmacol. 2013, 4, 69. [CrossRef]

41. Gudi, S.K.; Kashyap, A.; Chhabra, M.; Rashid, M.; Tiwari, K.K. Impact of pharmacist-led home medicines review services on drug-related problems among the elderly population: A systematic review. Epidemiol. Health 2019, 41, e2019020. [CrossRef] [PubMed]

42. Tecklenborg, S.; Byrne, C.; Cahir, C.; Brown, L.; Bennett, K. Interventions to Reduce Adverse Drug Event-Related Outcomes in Older Adults: A Systematic Review and Meta-analysis. Drugs Aging 2020, 37, 91–98. [CrossRef] [PubMed]

43. Thiruchelvam, K.; Hasan, S.S.; Wong, P.S.; Kairuz, T. Residential Aged Care Medication Review to Improve the Quality of Medication Use: A Systematic Review. J. Am. Med. Dir. Assoc. 2017, 18, 87.e1–87.e14. [CrossRef]

44. Yuan, C.; Ding, Y.; Zhou, K.; Huang, Y.; Xi, X. Clinical outcomes of community pharmacy services: A systematic review and meta-analysis. Health Soc. Care Community 2019, 27, e567–e587. [CrossRef] [PubMed]

45. Al-Babtain, B.; Cheema, E.; Hadi, M.A. Impact of community-pharmacist-led medication review programme on patients outcome: A systematic review and meta-analysis. Res. Soc. Adm. Pharm. 2021, in press. [CrossRef] [PubMed]

46. Dawoud, D.M.; Haines, A.; Wonderling, D.; Ashe, J.; Hill, J.; Varia, M.; Dyer, P.; Bion, J. Cost Effectiveness of Advanced Pharmacy Services Provided in the Community and Primary Care Settings: A Systematic Review. Pharmacoeconomics 2019, 37, 1241–1260. [CrossRef] [PubMed]

47. Milosavljevic, A.; Aspden, T.; Harrison, J. Community pharmacist-led interventions and their impact on patients’ medication adherence and other health outcomes: A systematic review. Int. J. Pharm. Pract. 2018, 26, 387–397. [CrossRef]

48. Varas-Doval, R.; Sáez-Benito, L.; Gastelurrutia, M.A.; Benrimoj, S.I.; García-Cárdenas, V.; Martínez-Martínez, F. Systematic review of pragmatic control trials assessing the effectiveness of professional pharmacy services in community pharmacies. BMC Health Serv. Res. 2021, 21, 156. [CrossRef] [PubMed]

49. Dou, C.; Rebane, J.; Bardal, S. Interventions to improve benzodiazepine tapering success in the elderly: A systematic review. Aging Ment. Health 2018, 23, 411–416. [CrossRef]

50. Reeve, E.; Ong, M.; Wu, A.; Jansen, J.; Petrovic, M.; Gnijdic, D. A systematic review of interventions to de-prescribe benzodiazepines and other hypnotics among older people. Eur. J. Clin. Pharmacol. 2017, 73, 927–935. [CrossRef]

51. Huiskes, V.J.B.; Burger, D.M.; van den Ende, C.H.M.; van den Bermt, B.J.F. Effectiveness of medication review: A systematic review and meta-analysis of randomized controlled trials. BMC Fam. Pract. 2017, 18, 5. [CrossRef]

52. Holland, R.; Desborough, J.; Goodyer, L.; Hall, S.; Wright, D.; Loke, Y.K. Does pharmacist-led medication review help to reduce hospital admissions and deaths in older people? A systematic review and meta-analysis. Br. J. Clin. Pharmacol. 2008, 65, 303–316. [CrossRef]

53. wallerstedt, S.M.; Kindblom, J.; Nylén, K.; Samuelsson, O.; Strandell, A. Medication reviews for nursing home residents to reduce mortality and hospitalization: Systematic review and meta-analysis. Br. J. Clin. Pharmacol. 2014, 78, 488–497. [CrossRef] [PubMed]

54. Hart, L.A.; Phelan, E.A.; Yi, J.Y.; Marcum, Z.A.; Gray, S.L. Use of Fall Risk–Increasing Drugs Around a Fall-Related Injury in Older Adults: A Systematic Review. J. Am. Geriatr. Soc. 2020, 68, 1334–1343. [CrossRef] [PubMed]

55. Crilly, P.; Kayyali, R. A Systematic Review of Randomized Controlled Trials of Telehealth and Digital Technology Use by Community Pharmacists to Improve Public Health. Pharmacy 2020, 8, 137. [CrossRef] [PubMed]

56. Barton, S. Which clinical studies provide the best evidence? The best RCT still trumps the best observational study. BMJ 2000, 321, 255–256. [CrossRef] [PubMed]